On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
On May 24, 2022, scientists at the Broad Institute of MIT and Harvard and the University of Massachusetts…
On May 19, 2022, the U.S. National Institutes of Health (NIH) announced that people who reported in a…
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
On May 18, 2022, scientists at the Centers for Disease Control and Prevention (CDC) announced that they were…
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
On Apr. 19, 2022, Moderna announced new clinical data on its bivalent COVID-19 booster platform including data on…
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
On Mar. 31, 2022, the National Institutes of Health (NIH) and Moderna announced a phase 2 clinical trial…
On Mar. 30, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service confirmed the…
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
On Mar. 21, 2022, Moderna announced announced a supply agreement with the Swiss Federal Government for seven million…
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Mar. 9, 2022, Harvard Medical School announced that an international research team had completed an atlas of…
On Mar. 7, 2022, Moderna announced that with the assistance of the U.S. Government, it had entered into…
On Mar. 1, 2022, Yield10 Bioscience announced that 2021 field test results showed that the trait C3020 tested…
On Feb. 28, 2022, the Patent and Trial Appeal Board of the U.S. Patent and Trademark Office (USPTO)…
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…